Literature DB >> 19543785

Reduction of neointimal hyperplasia in porcine coronary arteries by 2-deoxy-D-glucose.

Holger M Nef1, Helge Möllmann, Astrid Joseph, Christian Troidl, Sandra Voss, Maximilian Rauch, Ralf Kinscherf, Achim Vogt, Michael Weber, Christian W Hamm, Albrecht Elsässer.   

Abstract

BACKGROUND: The drug eluting stents have been shown to play a substantial role in preventing in-stent restenosis. This study was initiated to determine the efficacy of 2-deoxy-D-glucose (2-DG) in an in-stent restenosis model for reducing neointimal hyperplasia after coronary stent placement.
METHODS: In a porcine overstretch model, three kinds of stents were investigated (n = 12 per group): bare metal stents (BMS), rapamycin-eluted stents (RES), and BMS after intracoronary short-term application of 2-DG (DGS). After 42 days histomorphometric and histopathological analyses were performed.
RESULTS: Neointimal thickness (BMS: 0.38 +/- 0.08, RES: 0.24 +/- 0.11, DGS: 0.15 +/- 0.01), area stenosis (BMS: 47.39 +/- 2.76, RES: 32.2 +/- 2.08, DGS: 29.30 +/- 2.98) did not differ after 42 days between the RES and DGS but were significantly lower as compared to BMS only. Lumen area (BMS: 3.15 +/- 1.53, RES: 4.37 +/- 1.72, DGS: 4.77 +/- 2.14) was significantly higher in the DGS group in comparison to the BMS group. The calculated injury and inflammation scores were similar and re-endothelialization was confirmed in all groups.
CONCLUSIONS: This study could demonstrate that in porcine stent model neointimal hyperplasia and re-endothelialization after application of 2-DG are comparable to those seen in RES. Thus, 2-DG might be a promising clinical application for coronary stent coating.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19543785     DOI: 10.1007/s00392-009-0020-6

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  33 in total

Review 1.  The porcine coronary model of in-stent restenosis: current status in the era of drug-eluting stents.

Authors:  Harry C Lowe; Robert S Schwartz; Briain D Mac Neill; Ik-Kyung Jang; Motoya Hayase; Campbell Rogers; Stephen N Oesterle
Journal:  Catheter Cardiovasc Interv       Date:  2003-12       Impact factor: 2.692

2.  Successful local antiproliferative paclitaxel delivery in a repeatedly restenosed lesion of the right coronary artery after drug eluting-stent implantation.

Authors:  C Herdeg; K Göhring-Frischholz; U Helber; T Geisler; A May; K K Haase; M Gawaz
Journal:  Clin Res Cardiol       Date:  2007-11-22       Impact factor: 5.460

3.  Metabolic control analysis of the Warburg-effect in proliferating vascular smooth muscle cells.

Authors:  Martina Werle; Jörg Kreuzer; Julia Höfele; Albrecht Elsässer; Cordula Ackermann; Hugo A Katus; Achim M Vogt
Journal:  J Biomed Sci       Date:  2005-11-09       Impact factor: 8.410

4.  Rapamycin reduces neointima formation during vascular injury.

Authors:  M Hilker; M Buerke; M Guckenbiehl; H Schwertz; J Bühler; W Moersig; U Hake; H Oelert
Journal:  Vasa       Date:  2003-02       Impact factor: 1.961

5.  Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating.

Authors:  Jörg Hausleiter; Adnan Kastrati; Rainer Wessely; Alban Dibra; Julinda Mehilli; Thomas Schratzenstaller; Isolde Graf; Magdalena Renke-Gluszko; Boris Behnisch; Josef Dirschinger; Erich Wintermantel; Albert Schömig
Journal:  Eur Heart J       Date:  2005-06-23       Impact factor: 29.983

6.  Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis.

Authors:  A W Heldman; L Cheng; G M Jenkins; P F Heller; D W Kim; M Ware; C Nater; R H Hruban; B Rezai; B S Abella; K E Bunge; J L Kinsella; S J Sollott; E G Lakatta; J A Brinker; W L Hunter; J P Froehlich
Journal:  Circulation       Date:  2001-05-08       Impact factor: 29.690

7.  Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.

Authors:  David R Holmes; Martin B Leon; Jeffrey W Moses; Jeffrey J Popma; Donald Cutlip; Peter J Fitzgerald; Charles Brown; Tim Fischell; Shing Chiu Wong; Mark Midei; David Snead; Richard E Kuntz
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

8.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

Authors:  Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

9.  Inhibition of glycolysis by 2-DG increases [Ca2+]i in pulmonary arterial smooth muscle cells.

Authors:  R T Bright; C G Salvaterra; L J Rubin; X J Yuan
Journal:  Am J Physiol       Date:  1995-08

10.  Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment.

Authors:  Ick-Mo Chung; Herman K Gold; Stephen M Schwartz; Yuji Ikari; Michael A Reidy; Thomas N Wight
Journal:  J Am Coll Cardiol       Date:  2002-12-18       Impact factor: 24.094

View more
  1 in total

Review 1.  Nanotechnology in interventional cardiology.

Authors:  Tillmann Cyrus; Samuel A Wickline; Gregory M Lanza
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-07-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.